Trump FDA Nominee Dr. Heidi Overton Expected to Face Questions on Mifepristone Safety Review
President Trump has nominated Dr. Heidi Overton, currently his deputy assistant for domestic policy, to lead the FDA. Overton has publicly criticized mifepristone and previously served as chief policy officer at the America First Policy Institute. Her confirmation hearing has not been scheduled but is expected after the Senate returns from recess on September 14.
Single source · Not corroborated
Dr. Heidi Overton's nomination to lead the Food and Drug Administration has drawn attention from pro-life advocates who see her as likely to pursue tighter restrictions on mifepristone, the medication used in approximately 65% of clinician-provided abortions in 2023, according to the Guttmacher Institute.
John Mize, CEO of Americans United for Life — described by Fox News as the nation's oldest pro-life organization — said he has had five or six conversations with Overton and expressed confidence that she would "bring objectivity to the issue of mifepristone in a way that will expose this drug for the damage it causes women." Mize told Fox News Digital that his organization is "optimistic" Overton will be a "pro-life FDA commissioner."
Mifepristone currently carries an FDA boxed warning — the agency's strongest safety designation — for the risk of serious and sometimes fatal infections or bleeding. The FDA removed the in-person dispensing requirement in 2021, initially prompted by COVID-19 pandemic restrictions, and later made that change permanent following a safety data review. Under current rules, the drug can be prescribed via telehealth and mailed by certified pharmacies. Mize said he wants those rules tightened.